CANY
CPRX

Caxton Associates (New York)’s Catalyst Pharmaceutical CPRX Stock Holding History

Caxton Associates (New York)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,762
Closed -$413K – 524
2024
Q3 		$413K Buy
+20,762
New +$385K 0.02% 390
2022
Q3 		– Sell
-32,338
Closed -$227K – 503
2022
Q2 		$227K Sell
32,338
-92,264
-74% -$677K 0.02% 447
2022
Q1 		$1.03M Buy
124,602
+83,992
+207% +$594K 0.08% 101
2021
Q4 		$275K Hold
40,610
– – 0.03% 433
2021
Q3 		$215K Sell
40,610
-2,413
-6% -$13.2K 0.02% 388
2021
Q2 		$247K Buy
43,023
+18,431
+75% +$95.1K 0.03% 366
2021
Q1 		$113K Hold
24,592
– – 0.01% 398
2020
Q4 		$82K Buy
24,592
+13,039
+113% +$43.8K 0.01% 135
2020
Q3 		$34K Sell
11,553
-94,149
-89% -$368K ﹤0.01% 289
2020
Q2 		$488K Buy
105,702
+79,622
+305% +$358K 0.04% 145
2020
Q1 		$100K Buy
+26,080
New +$107K 0.02% 385

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Caxton Associates (New York)'s CPRX Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 20,762 shares — an estimated $413K sold.

Caxton Associates (New York) first reported a position in CPRX in Q1 2020 and held it in 11 quarters. The position peaked at $1.03M in Q1 2022. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 20,762 Catalyst Pharmaceutical shares in Q4 2024, an estimated $413K.
  • Caxton Associates (New York) first reported a position in Catalyst Pharmaceutical in Q1 2020 and held it in 11 quarters.
  • Caxton Associates (New York)'s Catalyst Pharmaceutical position peaked at $1.03M in Q1 2022.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.